Compare CRVO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRVO | ELUT |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 48.3M |
| IPO Year | 2011 | 2020 |
| Metric | CRVO | ELUT |
|---|---|---|
| Price | $3.70 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $23.00 | $6.00 |
| AVG Volume (30 Days) | 31.8K | ★ 62.4K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | $4,006,510.00 | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | ★ N/A | $1.17 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.51 | $0.50 |
| 52 Week High | $13.13 | $2.60 |
| Indicator | CRVO | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 39.03 |
| Support Level | $3.55 | $1.00 |
| Resistance Level | $4.33 | $1.18 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 2.67 | 4.87 |
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.